Tilray Brands Inc

This committee provides the official revenue estimates and analysis for all tax legislation. Its technical expertise and reports on proposed tax changes, especially regarding 280E reform, are critical to the legislative process and would directly impact Tilray Brands' financial future, making members privy to material non-public information.

This committee controls taxation. Changes to federal tax policy, particularly reform of the 280E tax code (which heavily impacts cannabis companies by disallowing normal business deductions), would directly and significantly affect Tilray Brands' profitability and valuation. Members would have access to critical legislative details.

The Farm Bill, overseen by this committee, legalized hemp and profoundly impacts Tilray Brands' hemp-derived product lines. Future Farm Bills or related legislation defining hemp and cannabis could directly affect the company's legal operating environment, making this committee a critical source of relevant information.

This committee regulates the FDA, NIH, and drug approval processes. Any changes to FDA's stance on cannabis/CBD products, potential rescheduling under the CSA, or new approval pathways for botanical medicines would directly impact Tilray Brands' core business model and product legality.

This committee's oversight of the DOJ, federal drug laws, and intellectual property is paramount. Any legislative action on decriminalization, rescheduling, or legalization of cannabis would fall directly under its purview, providing members with highly material, non-public information affecting Tilray Brands.

This committee is crucial for the cannabis industry. Regulatory changes to allow access to traditional banking services (e.g., SAFE Banking Act) would directly and significantly impact Tilray Brands' ability to operate, manage finances, and access capital, making it a primary source of material non-public information for the sector.